Literature DB >> 21073668

COMT Val158Met-stress interaction in psychosis: role of background psychosis risk.

Dina Collip1, Ruud van Winkel, Odette Peerbooms, Tineke Lataster, Viviane Thewissen, Marielle Lardinois, Marjan Drukker, Bart P F Rutten, Jim Van Os, Inez Myin-Germeys.   

Abstract

BACKGROUND: The interplay between the catechol-O-methyltransferase (COMT) Val158Met polymorphism and environmental stress may have etiological relevance for psychosis, but differential effects have been reported in healthy control and patient groups, suggesting that COMT Val158Met interactions with stress may be conditional on background genetic risk for psychotic disorder.
METHODS: Patients with a nonaffective psychotic disorder (n = 86) and control participants (n = 109) were studied with the experience sampling method (a structured diary technique) in order to assess stress, negative affect and momentary psychotic symptoms in the flow of daily life.
RESULTS: Multilevel analyses revealed significant three-way interactions between group status (patient or control), COMT genotype and stress in the model of negative affect (χ(2)(2) = 13.26, P < 0.01) as well as in the model of momentary psychotic symptoms (χ(2)(2) = 6.92, P < 0.05). Exploration of the three-way interaction revealed that in patients, COMT genotype moderated the association between stress and negative affect (χ(2)(4) = 11.50, P < 0.005), as well as the association between stress and momentary psychosis (χ(2)(4) = 12.79, P < 0.005). Met/Met genotype patients showed significantly increased psychotic and affective reactivity to stress in comparison to the Val/Met and Val/Val genotypes. In contrast, healthy controls did not display large or significant COMT Val158Met X stress interactions.
CONCLUSIONS: Important differences exist in the effect of COMT Val158Met on stress reactivity, which may depend on background risk for psychotic disorder. Differential sensitivity to environmental stress occasioned by COMT Val158Met may be contingent on higher order interactions with genetic variation underlying psychotic disorder.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21073668      PMCID: PMC6493901          DOI: 10.1111/j.1755-5949.2010.00213.x

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  35 in total

1.  Patient compliance with paper and electronic diaries.

Authors:  Arthur A Stone; Saul Shiffman; Joseph E Schwartz; Joan E Broderick; Michael R Hufford
Journal:  Control Clin Trials       Date:  2003-04

Review 2.  Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: a large-scale association study plus meta-analysis.

Authors:  Jin-Bo Fan; Chang-Shun Zhang; Niu-Fan Gu; Xing-Wang Li; Wei-Wei Sun; Hong-Yan Wang; Guo-Yin Feng; David St Clair; Lin He
Journal:  Biol Psychiatry       Date:  2005-01-15       Impact factor: 13.382

3.  Emotional reactivity to daily life stress in psychosis.

Authors:  I Myin-Germeys; J van Os; J E Schwartz; A A Stone; P A Delespaul
Journal:  Arch Gen Psychiatry       Date:  2001-12

4.  Determinants of occurrence and recovery from hallucinations in daily life.

Authors:  Philippe Delespaul; Marten deVries; Jim van Os
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2002-03       Impact factor: 4.328

5.  Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: a meta-analysis of case-control studies.

Authors:  M R Munafò; L Bowes; T G Clark; J Flint
Journal:  Mol Psychiatry       Date:  2005-08       Impact factor: 15.992

6.  Catechol-O-methyltransferase val158met genotype affects processing of emotional stimuli in the amygdala and prefrontal cortex.

Authors:  Michael N Smolka; Gunter Schumann; Jana Wrase; Sabine M Grüsser; Herta Flor; Karl Mann; Dieter F Braus; David Goldman; Christian Büchel; Andreas Heinz
Journal:  J Neurosci       Date:  2005-01-26       Impact factor: 6.167

7.  COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor.

Authors:  Jon-Kar Zubieta; Mary M Heitzeg; Yolanda R Smith; Joshua A Bueller; Ke Xu; Yanjun Xu; Robert A Koeppe; Christian S Stohler; David Goldman
Journal:  Science       Date:  2003-02-21       Impact factor: 47.728

8.  Emotional reactivity to daily life stress in psychosis and affective disorder: an experience sampling study.

Authors:  I Myin-Germeys; F Peeters; R Havermans; N A Nicolson; M W DeVries; P Delespaul; J Van Os
Journal:  Acta Psychiatr Scand       Date:  2003-02       Impact factor: 6.392

9.  Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction.

Authors:  Avshalom Caspi; Terrie E Moffitt; Mary Cannon; Joseph McClay; Robin Murray; HonaLee Harrington; Alan Taylor; Louise Arseneault; Ben Williams; Antony Braithwaite; Richie Poulton; Ian W Craig
Journal:  Biol Psychiatry       Date:  2005-05-15       Impact factor: 13.382

Review 10.  Strategy for investigating interactions between measured genes and measured environments.

Authors:  Terrie E Moffitt; Avshalom Caspi; Michael Rutter
Journal:  Arch Gen Psychiatry       Date:  2005-05
View more
  23 in total

1.  Beyond DSM and ICD: introducing "precision diagnosis" for psychiatry using momentary assessment technology.

Authors:  Jim van Os; Philippe Delespaul; Johanna Wigman; Inez Myin-Germeys; Marieke Wichers
Journal:  World Psychiatry       Date:  2013-06       Impact factor: 49.548

Review 2.  Animal models of gene-environment interaction in schizophrenia: A dimensional perspective.

Authors:  Yavuz Ayhan; Ross McFarland; Mikhail V Pletnikov
Journal:  Prog Neurobiol       Date:  2015-10-25       Impact factor: 11.685

3.  [Trauma and psychosis--part 2. On the association of early childhood maltreatment and risk of psychosis in general population].

Authors:  Hans-Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2012-10-05

4.  COMT Val158Met Polymorphism and Symptom Improvement Following a Cognitively Focused Intervention for Irritable Bowel Syndrome.

Authors:  Claire J Han; Ruth Kohen; Sangeun Jun; Monica E Jarrett; Kevin C Cain; Robert Burr; Margaret M Heitkemper
Journal:  Nurs Res       Date:  2017 Mar/Apr       Impact factor: 2.381

5.  HPA axis function and symptoms in adolescents at clinical high risk for schizophrenia.

Authors:  C M Corcoran; C Smith; D McLaughlin; A Auther; D Malaspina; B Cornblatt
Journal:  Schizophr Res       Date:  2012-01-09       Impact factor: 4.939

Review 6.  The emerging molecular architecture of schizophrenia, polygenic risk scores and the clinical implications for GxE research.

Authors:  Conrad Iyegbe; Desmond Campbell; Amy Butler; Olesya Ajnakina; Pak Sham
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-01-17       Impact factor: 4.328

Review 7.  The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia.

Authors:  Oliver D Howes; Robert McCutcheon; Michael J Owen; Robin M Murray
Journal:  Biol Psychiatry       Date:  2016-08-06       Impact factor: 13.382

8.  COMT Val158Met polymorphism interacts with stressful life events and parental warmth to influence decision making.

Authors:  Qinghua He; Gui Xue; Chuansheng Chen; Zhong-Lin Lu; Chunhui Chen; Xuemei Lei; Yuyun Liu; Jin Li; Bi Zhu; Robert K Moyzis; Qi Dong; Antoine Bechara
Journal:  Sci Rep       Date:  2012-09-20       Impact factor: 4.379

9.  COMT Val158Met genotype selectively alters prefrontal [18F]fallypride displacement and subjective feelings of stress in response to a psychosocial stress challenge.

Authors:  Dennis Hernaus; Dina Collip; Johan Lataster; Jenny Ceccarini; Gunther Kenis; Linda Booij; Jens Pruessner; Koen Van Laere; Ruud van Winkel; Jim van Os; Inez Myin-Germeys
Journal:  PLoS One       Date:  2013-06-14       Impact factor: 3.240

10.  A meta-analysis of the Val158Met COMT polymorphism and violent behavior in schizophrenia.

Authors:  Jay P Singh; Jan Volavka; Pál Czobor; Richard A Van Dorn
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.